Jeil Pharmaceutical's 'Zaqubo' Surpasses 10 Billion Won in Monthly Prescription Sales Just Two Years After Launch

October outpatient prescription sales reach 10.3 billion won
Phase 3 trials underway to add four indications

Jeil Pharmaceutical's gastroesophageal reflux disease treatment Zaqubo (active ingredient: zastaprazan) surpassed 10 billion won in monthly prescription sales just two years after its launch. It also entered the top 10 for the first time in the ranking of prescription sales for ethical drugs in South Korea.

Product image of Jeil Pharmaceutical's treatment for gastroesophageal reflux disease, Zaqbo (active ingredient: zastaprazan). Jeil Pharmaceutical

According to pharmaceutical market research firm UBIST on November 10, Zaqubo generated 10.3 billion won in outpatient prescription sales in October. This was the first time its monthly prescription sales exceeded 10 billion won.

Zaqubo is a new potassium-competitive acid blocker (P-CAB) developed by Onconic Therapeutics, a drug development subsidiary of Jeil Pharmaceutical. It was launched in October 2024 as South Korea's 37th domestically developed new drug. Its advantages include taking effect faster than existing proton pump inhibitors (PPIs), suppressing gastric acid secretion for longer overnight, and being taken regardless of meals.

Jeil Pharmaceutical is accelerating Zaqubo's establishment in the market through co-marketing with Dong-A ST, which has a strong presence in gastroenterology. The drug added a gastric ulcer indication in June 2025, and an orally disintegrating tablet that can be taken without water was launched in January 2026. Phase 3 clinical trials are currently underway to add four indications: non-erosive gastroesophageal reflux disease, Helicobacter pylori eradication therapy, maintenance treatment for erosive gastroesophageal reflux disease, and prevention of peptic ulcers caused by anti-inflammatory analgesics.

Overseas expansion is also continuing. Zaqubo is currently available in 28 countries, including China and India. It received its first overseas product approval in India in August 2026, while its Chinese partner, Livzon Pharmaceutical, is going through the approval process.

A Jeil Pharmaceutical representative said, "The fact that a domestically developed new drug surpassed 10 billion won in monthly outpatient prescription sales just two years after its launch and entered the top 10 in the overall ethical drug market means that Zaqubo has established itself as a major treatment option in South Korea's P-CAB market." The representative added, "We will expand the areas in which it can be prescribed by securing additional indications and increase Zaqubo's value in global markets."

This content was produced with the assistance of AI translation services.